First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (vol 124, pg 1222, 2021)

被引：0
|
作者：
van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.
机构：
[1] Dutch Institute for Clinical Auditing,Department of Medical Oncology, Amsterdam UMC
[2] VU University Medical Center,Department of Surgical Oncology
[3] Cancer Center Amsterdam,Department of Pharmacy
[4] Netherlands Cancer Institute,Department of Medical Oncology and Immunology
[5] Rode Kruis Ziekenhuis,Department of Molecular Oncology & Immunology
[6] Netherlands Cancer Institute,Department of Medical Oncology
[7] Netherlands Cancer Institute,Department of Medical Oncology
[8] Maastricht University Medical Centre,Department of Medical Oncology
[9] Zuyderland Medical Centre Sittard,Department of Medical Oncology
[10] Isala Oncology Center,Department of Internal Medicine
[11] Isala,Department of Internal Medicine
[12] University Medical Centre Groningen,Department of Medical Oncology
[13] Leiden University Medical Centre,Department of Pathology, Division of Laboratories, Pharmacy and Biomedical Genetics
[14] Medisch Spectrum Twente,Department of Internal Medicine
[15] Medical Centre Leeuwarden,Departments of Medical Oncology and Radiology & Nuclear Medicine
[16] University Medical Centre Utrecht,Department of Internal Medicine
[17] University Medical Center Utrecht,Department of Medical Oncology
[18] Amphia Hospital,undefined
[19] Erasmus Medical Centre,undefined
[20] Maxima Medical Centre,undefined
[21] Radboud University Medical Centre,undefined
来源：
BRITISH JOURNAL OF CANCER | 2021年 / 124卷 / 10期
关键词：
D O I：
10.1038/s41416-021-01312-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1
引用
收藏
页码：1746 / 1746
页数：1
相关论文
共 22 条
  • [1] First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
    van Breeschoten, Jesper
    Wouters, Michel W. J. M.
    Hilarius, Doranne L.
    Haanen, John B.
    Blank, Christian U.
    Aarts, Maureen J. B.
    van den Berkmortel, Franchette W. P. J.
    de Groot, Jan-Willem B.
    Hospers, Geke A. P.
    Kapiteijn, Ellen
    Piersma, Djura
    van Rijn, Roos S.
    Suijkerbuijk, Karijn P. M.
    Blokx, Willeke A. M.
    Tije, Bert-Jan J. ten
    Veldt, Astrid A. M. van der
    Vreugdenhil, Art
    Boers-Sonderen, Marye J.
    van den Eertwegh, Alfonsus J. M.
    BRITISH JOURNAL OF CANCER, 2021, 124 (07) : 1222 - 1230
  • [2] First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
    Jesper van Breeschoten
    Michel W. J. M. Wouters
    Doranne L. Hilarius
    John B. Haanen
    Christian U. Blank
    Maureen J. B. Aarts
    Franchette W. P. J. van den Berkmortel
    Jan-Willem B. de Groot
    Geke A. P. Hospers
    Ellen Kapiteijn
    Djura Piersma
    Roos S. van Rijn
    Karijn P. M. Suijkerbuijk
    Willeke A. M. Blokx
    Bert-Jan J. ten Tije
    Astrid A. M. van der Veldt
    Art Vreugdenhil
    Marye J. Boers-Sonderen
    Alfonsus J. M. van den Eertwegh
    British Journal of Cancer, 2021, 124 : 1222 - 1230
  • [3] Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
    Jesper van Breeschoten
    Michel W. J. M. Wouters
    Doranne L. Hilarius
    John B. Haanen
    Christian U. Blank
    Maureen J. B. Aarts
    Franchette W. P. J. van den Berkmortel
    Jan-Willem B. de Groot
    Geke A. P. Hospers
    Ellen Kapiteijn
    Djura Piersma
    Roos S. van Rijn
    Karijn P. M. Suijkerbuijk
    Willeke A. M. Blokx
    Bert-Jan J. ten Tije
    Astrid A. M. van der Veldt
    Art Vreugdenhil
    Marye J. Boers-Sonderen
    Alfonsus J. M. van den Eertwegh
    British Journal of Cancer, 2022, 126 : 1362 - 1362
  • [4] First-line BRAF/MEK-inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: A propensity-matched survival analysis
    Breeschoten, J. V.
    Wouters, M.
    Hilarius, D.
    Haanen, J. B. A. G.
    Blank, C. U.
    Aarts, M.
    Van den Berkmortel, F.
    de Groot, J. W.
    Hospers, G. A.
    Kapiteijn, E.
    Piersma, D.
    Van Rijn, R.
    Suijkerbuijk, K.
    Blokx, W. A. M.
    Ten Tije, A.
    Van der Veldt, A. A. M.
    Vreugdenhil, G.
    Boers-Sonderen, M.
    van den Eertwegh, A. J. M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1431 - S1431
  • [5] Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
    Jesper van Breeschoten
    Michel W. J. M. Wouters
    Doranne L. Hilarius
    John B. Haanen
    Christian U. Blank
    Maureen J. B. Aarts
    Franchette W. P. J. van den Berkmortel
    Jan-Willem B. de Groot
    Geke A. P. Hospers
    Ellen Kapiteijn
    Djura Piersma
    Roos S. van Rijn
    Karijn P. M. Suijkerbuijk
    Willeke A. M. Blokx
    Bert-Jan J. ten Tije
    Astrid A. M. van der Veldt
    Art Vreugdenhil
    Marye J. Boers-Sonderen
    Alfonsus J. M. van den Eertwegh
    British Journal of Cancer, 2021, 124 : 1746 - 1746
  • [6] First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (Mar, 10.1038/s41416-022-01772-z, 2022)
    van Breeschoten, Jesper
    Wouters, Michel W. J. M.
    Hilarius, Doranne L.
    Haanen, John B.
    Blank, Christian U.
    Aarts, Maureen J. B.
    van den Berkmortel, Franchette W. P. J.
    de Groot, Jan-Willem B.
    Hospers, Geke A. P.
    Kapiteijn, Ellen
    Piersma, Djura
    van Rijn, Roos S.
    Suijkerbuijk, Karijn P. M.
    Blokx, Willeke A. M.
    ten Tije, Bert-Jan J.
    van der Veldt, Astrid A. M.
    Vreugdenhil, Art
    Boers-Sonderen, Marye J.
    van den Eertwegh, Alfonsus J. M.
    BRITISH JOURNAL OF CANCER, 2022, 126 (09) : 1362 - 1362
  • [7] Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis
    De Meza, Melissa M. M.
    Blokx, Willeke A. M.
    Bonenkamp, Johannes J. J.
    Blank, Christian U. U.
    Aarts, Maureen J. B.
    van den Berkmortel, Franchette W. P. J.
    Boers-Sonderen, Marye J. J.
    De Groot, Jan Willem B.
    Haanen, John B. A. G.
    Hospers, Geke A. P.
    Kapiteijn, Ellen
    Van Not, Olivier J. J.
    Piersma, Djura
    Van Rijn, Rozemarijn S. S.
    Stevense-den Boer, Marion
    van der Veldt, Astrid A. M.
    Vreugdenhil, Gerard
    van den Eertwegh, Alfonsus J. M.
    Suijkerbuijk, Karijn P. M.
    Wouters, Michel W. J. M.
    CANCERS, 2023, 15 (02)
  • [8] Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: Propensity score-matched recurrence-free, distant metastasis-free, and overall survival analysis
    Bloem, Manja
    de Meza, Melissa Melanie
    Aarts, Maureen J. B.
    Van den Berkmortel, Franchette
    Blank, Christian U.
    Blokx, Willeke
    Boers-Sonderen, Marye J.
    Bonenkamp, Han J.
    de Groot, Jan Willem
    Haanen, John
    Hospers, Geke
    Kapiteijn, Ellen
    Piersma, Djura
    van Rijn, Rozemarijn
    Stevense-den Boer, Marion
    Van der Veldt, Astrid Aplonia Maria
    Vreugdenhil, Gerard
    van den Eertwegh, Alfonsus Johannes Maria
    Suijkerbuijk, Karijn
    Wouters, Michel W. J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab
    Moser, Justin C.
    Chen, Danli
    Hu-Lieskovan, Siwen
    Grossmann, Kenneth F.
    Patel, Shiven
    Colonna, Sarah, V
    Ying, Jian
    Hyngstrom, John R.
    CANCER MEDICINE, 2019, 8 (18): : 7637 - 7643
  • [10] Addition of anti-PD-1 immunotherapy to BRAF inhibitor-based targeted therapy improves real-world survival and delays brain metastases in patients with BRAFV600-mutant advanced melanoma: a multicenter cohort study
    Wu, Junwan
    Ding, Qiuyue
    Zhang, Qiong
    Chen, Qianqi
    Wen, Xizhi
    Ding, Ya
    Li, Jingjing
    Chen, Ziluan
    Zhang, Tao
    Wang, Jiuhong
    Huang, Fuxue
    Jiang, Hang
    Chen, Linbin
    Zhou, Qiming
    Li, Ke
    Zhang, Xiaoshi
    Li, Dandan
    MEDCOMM, 2025, 6 (03):
123